Information Provided By: 
Fly News Breaks for November 30, 2018
HOLX
Nov 30, 2018 | 09:13 EDT
RBC Capital analyst Glenn Novarro raised his price target on Hologic to $46 to reflect the update in his valuation model. The analyst believes that "the worst is behind" the company with regards to Cynosure and assumes that its business will return to mid-to-high single digit revenue growth in FY20. Novarro keeps his rating on Hologic at Sector Perform however, saying that the stock remains a "show-me" story and that its valuation appears reasonable based on the company's current growth profile.
News For HOLX From the Last 2 Days
There are no results for your query HOLX
